– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif.
– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a PIPE, led by Perceptive Advisors and RA Capital, and funds held by Perceptive Capital Solutions
– Updated test version achieved significant performance improvement in detecting advanced precancerous lesions, including those with high-grade dysplasia – Modeling projects the improvements would translate to 1,582 additional life-years gained (7.7%), 426 fewer CRC cases (9.5%) and 143 fewer CRC
– Extraordinary General Meeting of Perceptive Shareholders Scheduled for July 9, 2026 NEW YORK and BRISBANE, Calif., June 18, 2026 /PRNewswire/ — Perceptive Capital Solutions Corp (“PCSC”) (Nasdaq: PCSC), a special purpose acquisition company (“SPAC”) sponsored by an affiliate of Perceptive
– Guideline includes new category – blood-based tests – that represents a broader shift in cancer screening toward minimally invasive approaches that may improve screening rates – SimpleScreen CRC is under FDA review with approval anticipated in mid 2026 Brisbane, CA (May 27, 2026) — Freenome, an
– The data, generated from a study designed to optimize ongoing test refinement, will be presented at the AACR Annual Meeting in April – Brisbane, CA (March 18, 2026) — Freenome, an early cancer detection company developing blood-based screening tests, today announced initial development data for
– Collaboration is designed to improve analytical speed and accuracy of Freenome’s blood-based cancer screening tests – Brisbane, CA (Jan. 12, 2026) — Freenome today announced an initiative to advance its blood-based early cancer screening program by leveraging NVIDIA deep learning technology and
– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test’s first version, which is currently under FDA review – – Assay upgrades led to improved detection rates, limit of detection
